MK-2206 2HCl

Bezeichnung:MK-2206 2HCl

CAS-Nr1032350-13-2

Englisch Name:MK-2206 2HCl

CBNumberCB72489901

SummenformelC25H22ClN5O

Molgewicht443.94

MOL-Datei1032350-13-2.mol

MK-2206 2HCl physikalisch-chemischer Eigenschaften

Schmelzpunkt	>255°C (dec.)
storage temp.	-20°C
Löslichkeit	Soluble in DMSO (up to 10 mg/ml with warming)
Aggregatzustand	Yellow powder.
Farbe	Yellow
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Sicherheit

HS Code

2933998090

Gefahreninformationscode (GHS)

MK-2206 2HCl Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
MK-2206 (CAS 1032350-13-2) is a potent and selective allosteric inhibitor of Akt (IC50’s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the?in vitro?and?in vivo?antitumor efficacy of several standard chemotherapeutic agents.1?It was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle.2?MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis.3
Verwenden
AZD 6244 and MK 2206 are targeted small-molecule drugs that inhibit MEK and AKT responses. The combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors. Antitumor agents. Potent AKT inhibitor.
Verwenden
A highly selective inhibitor of Akt. Akt1, IC50=8 nM; Akt2, IC50=12 nM; Akt3, IC50=65 nM.
Verwenden
AZD 6244 and MK 2206 are targeted small-molecule drugs that inhibit MEK and AKT responses. The combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vi vo and leads to increased survival rates in mice bearing highly aggressive human lung tumors. Antitumor agents.
target
Akt1
Lager
-20°C
Einzelnachweise
1) Hirai?et al.?(2010),?MK-2206, an Allosteric Akt inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular targeted Drugs In vitro and In vivo; Mol. Cancer Ther.?9?1956 2) Lai?et al.?(2012),?A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle; Biochem. J.?447?137 3) Jiao?et al.?(2013),?MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death; Mol. Cell Biochem.?382?217

MK-2206 2HCl Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

1032350-13-2, MK-2206 2HCl Verwandte Suche:

Send Inquriy